EP4199943A1 - Composition comprenant du miel manuka et de la phycobiliprotéine - Google Patents

Composition comprenant du miel manuka et de la phycobiliprotéine

Info

Publication number
EP4199943A1
EP4199943A1 EP21763016.9A EP21763016A EP4199943A1 EP 4199943 A1 EP4199943 A1 EP 4199943A1 EP 21763016 A EP21763016 A EP 21763016A EP 4199943 A1 EP4199943 A1 EP 4199943A1
Authority
EP
European Patent Office
Prior art keywords
honey
composition
range
manuka honey
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21763016.9A
Other languages
German (de)
English (en)
Inventor
Peter Josef Johannes TITZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AAA Accelerator Group Europe AG
Original Assignee
AAA Accelerator Group Europe AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AAA Accelerator Group Europe AG filed Critical AAA Accelerator Group Europe AG
Publication of EP4199943A1 publication Critical patent/EP4199943A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
    • A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
    • A23L21/25—Honey; Honey substitutes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/748—Cyanobacteria, i.e. blue-green bacteria or blue-green algae, e.g. spirulina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Definitions

  • the present invention relates to a composition which comprises manuka honey and phycobiliprotein and is characterized by a storage stability of at least 18 months at room temperature.
  • honey has been important in human nutrition for thousands of years. In addition to the main sugars fructose and glucose as well as water, natural honey also contains small amounts of other di- and oligosaccharides, pollen, minerals, proteins, enzymes, amino acids, vitamins, coloring and flavoring substances. Honey has played an important role as a basis for high-calorie nutritional gels in the diet of athletes in particular.
  • honey has long been used in naturopathy, e.g. B. an anti-inflammatory effect was used.
  • Honey is also known to have a low antibacterial effect, which is attributed to the small proportion of peroxides in natural honey.
  • Manuka honey which is produced from the flower nectar of South Sea myrtle (Manuka; Latin: Leptospermum scopariuni), shows a significantly higher antibacterial and antifungal effect. In contrast to other types of honey, this effect is not based on a peroxide content, but on a high content of methylglyoxal.
  • DHA dihydroxyacetone
  • leptosperine which also occurs exclusively in the Manuka plant, are characteristic ingredients of real Manuka honey.
  • phycobiliproteins such as phycocyanin (C-PC) have gained particular importance, since they can not only serve as a supplier of amino acids, but also have activity in the treatment of cancer, inflammatory diseases, the prevention of angionesis and in the healing of certain autoimmune diseases are discussed.
  • C-PC phycocyanin
  • a disadvantage of phycobiliproteins is their low thermal stability.
  • the present invention is therefore based on the object of providing a composition comprising manuka honey and phycobiliprotein which has a storage stability of at least 18 months at room temperature.
  • the invention relates to a composition
  • a composition comprising manuka honey, phycobiliprotein and a standard honey, the composition having a total methylglyoxal concentration in the range of 30-65 mg/kg.
  • Manuka honey is to be understood as meaning honey that is produced from the flower nectar of South Sea myrtle (Manuka; lat.: Leptospermum scopariuni).
  • Manuka honey is characterized in particular by its high content of methylglyoxal, the presence of dihydroxyacetone, a content of at least 100 mg/kg leptosperine, and a quantity of hydroxymethylfurfural (HMF) that must not exceed 40 mg/kg.
  • HMF hydroxymethylfurfural
  • Standard honey means honey that, unlike Manuka honey, has only small traces of methylglyoxal, dihydroxyacetone and/or leptosperine and can come from different sources.
  • An example of a standard honey that is suitable for use in the context of the present invention is a pasteurized blossom honey.
  • “Phycobiliprotein” refers to a group of proteins in the form of chromoproteins with a relative molecular mass between 50,000 and 270,000, which absorb in the green to light red spectral range, i.e. between about 500 and 650 nm wavelength, as membrane-associated antenna pigments exclusively in cyanobacteria ), rhodophytes (red algae) and cryptophytes occur.
  • Total methylglyoxal concentration means the concentration of methylglyoxal in the composition according to the invention. This total methylglyoxal concentration can either be determined experimentally or calculated from the known UMF value of the Manuka honey used and the proportion of the composition that accounts for it.
  • the proportion x of the Manuka honey in the composition is in the range of 10-20 percent by weight, the proportion y of the phycobiliprotein in the range of 1.5-4.0 percent by weight and the proportion z of the standard honey in the range of 75 - 84.5% by weight, and wherein the sum of x, y and z ranges from 95 to 100% by weight.
  • the proportion x of the Manuka honey in the composition is in the range of 19-20 percent by weight, the proportion y of the phycobiliprotein in the range of 1.5-4.0 percent by weight and the proportion z of the standard honey in the range of 77- 80 percent by weight.
  • the sum of the proportions x, y and z is 100 percent by weight.
  • the proportion x of the Manuka honey in the composition is 19.5 percent by weight
  • the proportion y of the phycobiliprotein is 1.5 percent by weight
  • the proportion z of the standard honey is 79 percent by weight.
  • the Manuka honey is characterized by a UMF value in the range from 10 to 15.
  • UMF Unique Manuka Factor
  • AMHA Active Manuka Honey Association Inc.
  • NPA non-peroxide activity
  • the UMF or NPA value is determined by comparing the antibacterial effect of Manuka honey in vitro with that of an aqueous phenol solution. For example, a Manuka honey with a UMF or NPA value of 30 has the same antibacterial effectiveness in vitro as a 30 percent phenol solution.
  • the Manuka honey is characterized by a UMF value of 11.
  • the Manuka honey is characterized by a methylglyoxal concentration in the range of 250 to 514 mg/kg.
  • the Manuka honey is characterized by a methylglyoxal concentration in the range from 250 to 310 mg/kg.
  • the Manuka honey is characterized by a methylglyoxal concentration of 307 mg/kg.
  • the composition has a total methylglyoxal concentration of 60 mg/kg.
  • the phycobiliprotein is selected from phycocyanin (C-PC), allophycocyanin (APC) and phycoerythrin (PE) or mixtures thereof.
  • the phycobiliprotein is a mixture of 55-65% phycocyanin (C-PC), 22-30% allophycocyanin (APC) and 12-20% phycoerythrin (PE), preferably 58% phycocyanin (C-PC), 26 % allophycocyanin (APC) and 16% phycoerythrin (PE).
  • the phycobiliprotein is a powdered crude extract of rhodophytes, cryptophytes or cyanobacteria, preferably a powdered crude extract of rhodophytes.
  • Figure 1 shows the time course of the phycocyanin content of a composition of Manuka honey (UMF value of 11; 98.5 percent by weight) and Phycocyanin Blue powder (crude extract from red algae; 1.5 percent by weight) without the addition of standard honey over a period of time of nine months.
  • Figure 1 shows the graph of an assumed linear decrease in protein content by 0.75% per month.
  • Figure 1 shows the graph of an assumed linear decrease in protein content by 0.75% per month.
  • Table 1 and FIG. 1 show the decrease in the protein content over a period of 9 months, with the maximum acceptable decrease (9%: see Table 2) for a total period of 12 months already being reached after three months.
  • Table 1 Decrease in Phycocyanin Content in Manuka Honey (UMF 11)
  • Table 3 and Figure 1 show the decrease in protein content over time over a period of 11 months, with this content stabilizing after an initial decrease and from about nine months showing a smaller decrease than in the case of a natural product for a total period of 12 months months is still acceptable (9%: see Table 2).
  • the phycocyanin content was determined as described in Example 1, and Table 3 also shows the course of the decrease in the individual components C-PC, APC and PE.
  • Table 3 Decrease in phycocyanin content in manuka honey (UMF 11)/honey mixture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Insects & Arthropods (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition qui comprend du miel manuka, de la phycobiliprotéine et du miel standard et qui est caractérisée par une stabilité au stockage d'au moins 18 mois à la température ambiante et par une concentration totale définie de méthylglyoxal.
EP21763016.9A 2020-08-20 2021-08-05 Composition comprenant du miel manuka et de la phycobiliprotéine Withdrawn EP4199943A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE202020104828.7U DE202020104828U1 (de) 2020-08-20 2020-08-20 Zusammensetzung umfassend Manuka-Honig und Phycobiliprotein
PCT/EP2021/071835 WO2022037951A1 (fr) 2020-08-20 2021-08-05 Composition comprenant du miel manuka et de la phycobiliprotéine

Publications (1)

Publication Number Publication Date
EP4199943A1 true EP4199943A1 (fr) 2023-06-28

Family

ID=73265072

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21763016.9A Withdrawn EP4199943A1 (fr) 2020-08-20 2021-08-05 Composition comprenant du miel manuka et de la phycobiliprotéine

Country Status (3)

Country Link
EP (1) EP4199943A1 (fr)
DE (1) DE202020104828U1 (fr)
WO (1) WO2022037951A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1011136B (el) * 2025-01-29 2026-02-16 Its Alive E.E., Συντηρηση καθαρης ετικετας φυκοκυανινης σε θερμοκρασια δωματιου με τη χρηση μελιου ή παρομοιων σιροπιων

Also Published As

Publication number Publication date
WO2022037951A1 (fr) 2022-02-24
DE202020104828U1 (de) 2020-10-27

Similar Documents

Publication Publication Date Title
DE69521158T2 (de) Proteinextrakt aus Cucumis melo mit Antioxydationswirkung und Verfahren zur Herstellung, kosmetische oder pharmazeutische Zubereitung oder Nahrungszubereitung die so ein Extrakt enthält
CH685282A5 (de) Antigeschwulstmittel und Verfahren zu ihrer Herstellung.
DE69907606T2 (de) Zusammensetzung, die Panax pseudo ginseng und Eucommiae ulmoides enthält
DE102009030351A1 (de) Zusammensetzung zur Behandlung von degenerativen Gelenkerkrankungen
EP1465641B1 (fr) Medicaments contenant du deuterium pour traiter le diabete
EP1784201B1 (fr) Composition physiologiquement active contre le diabete
DE69802545T2 (de) Propolis und mindestens ein ätherisches öl enthaltende zusammensetzung
EP4199943A1 (fr) Composition comprenant du miel manuka et de la phycobiliprotéine
EP0391886A1 (fr) Additif alimentaire
DE69017673T2 (de) Verminderung von post-prandial grossen neutralen aminosäureplasmakonzentrationen.
DE69826828T2 (de) Reverse Transkriptase Inhibitor aus Ulmus Hollandica
DE69802734T2 (de) Verwendung von Steviaextrakten zur Herstellung einer antihistaminischen Zusammensetzung
DE212019000123U1 (de) Hämatococcus pluvialis-Pulverzusammensetzung mit einer Antioxidationswirkung
DE1667887B1 (de) Aminosaeureloesungen zur parenteralen Infusion
DE102023123064A1 (de) Antioxidativ wirksame Zusammensetzung und deren Verwendung
DE69809375T2 (de) Antikrebs-Zubereitung
DE69619846T2 (de) Prophylaktische absorbierbare zubereitung mit protektiver wirkung gegen elektromagnetische wellen mit ionisierendem oder nicht ionisierendem effekt
DE60102142T2 (de) Kosmetische verwendung von hopfen und ornithin
DE69725749T2 (de) Substanz in form eines wässrigen extrakts von pflanzenrohmaterial zur behandlung onkologischer krankheiten sowie verfahren zu deren herstellung
DE60206545T2 (de) Zusammensetzung zum Trinken/Essen enthaltend AGARICUS BLAZEI MURRILL
DE202004017113U1 (de) Momordica charantia-Zimt-Zubereitung
WO2020038768A1 (fr) Boisson et mélange de solides pour sa fabrication
DE102018131724A1 (de) Zusammensetzung und Verwendung der Zusammensetzung als Anti-Aging-Mittel
EP2247276B1 (fr) Agent de croissance capillaire
DE102018007480A1 (de) Arznei- oder Nahrungsergänzungsmittel zur Aufrechterhaltung der Gesundheit von Gehirnzellen und/oder der Behandlung von geschädigten Gehirnzellen durch Aktivierung des Zellstoffwechsels der Gehirnzellen und/oder zum präventiven Schutz durch Erhöhung der Antioxidantien Konzentration im Gehirn.

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230301

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20231010